Best Nephrology Journals (2026): Ranked by Impact and Accessibility

In our pre-submission review work with kidney-disease, dialysis, transplant, CKD, biomarker, and renal-physiology manuscripts, the recurring failure is not a weak journal list. It is a mismatch between the manuscript's actual evidence level and the nephrology audience it asks to persuade. A large registry study, a podocyte mechanism paper, a dialysis quality-improvement project, and a transplant-immunology manuscript can all be "nephrology," but they should not be routed through the same journal logic.

Evidence basis: this page combines current local metric-owner pages, society and publisher journal pages, and Manusights manuscript-fit review patterns for clinical and translational nephrology submissions. The metric table is a shortlist aid, not a citation source. Use exact-title metric pages when the decision is a JIF lookup; use this page when the decision is where a kidney manuscript should be submitted.

This is the highest-impact title in nephrology, but it's almost entirely review and commentary content. You won't submit original research here. Instead, you'll need an invitation or a very compelling pitch for a review article. The readership is broad, and a publication here will get noticed across medicine, not just within nephrology. If you've been invited to write a review, take it seriously.

JASN is the flagship for original nephrology research in the US. It publishes across the full spectrum, from basic science to clinical epidemiology, but it favors work that connects mechanisms to clinical outcomes. The review process is thorough and usually constructive, though turnaround can stretch to 10 weeks. If your study changes how we understand a kidney disease or its treatment, JASN should be your first stop.

Kidney International is JASN's main rival and the top-tier journal of the International Society of Nephrology. It leans slightly more toward translational and clinical work compared to JASN's broader basic science coverage. European and international authors sometimes find a warmer reception here. The journal has a well-organized review process and provides detailed feedback even on rejected manuscripts.

AJKD is the clinical nephrology workhorse. It's the go-to for observational studies, clinical guidelines, and case-based teaching. If your paper is clinically oriented and practice-changing, AJKD is an excellent fit. It doesn't publish much basic science, so don't send your mouse model studies here. The readership is largely practicing nephrologists, which means your work will actually influence clinical decisions.

CJASN fills the gap between JASN and more accessible journals. It's selective but not impossibly so, and it values well-designed clinical studies, quality improvement research, and educational content. Review turnaround is faster than JASN on average. This is a strong choice for mid-career researchers building a clinical research portfolio.

NDT is the ERA's flagship journal and carries significant weight in European nephrology. It publishes a mix of clinical and translational research with a slight European bias in terms of study populations and healthcare system relevance. The review process can be slower than some competitors, but the editorial team provides substantive feedback. If your work addresses dialysis outcomes or transplant immunology, NDT should be on your shortlist.

This journal sits in a solid mid-range position. It's a reasonable target for well-executed clinical studies that may not have the novelty for JASN or Kidney International but still contribute meaningfully to the literature. Turnaround is relatively quick, and the acceptance rate around 25% makes it realistic for many research groups.

This is Kidney International's open access companion, and it's built a solid reputation quickly. It publishes work that's scientifically sound but may not reach the novelty threshold for the parent journal. The OA model means wider dissemination, and the connection to the ISN adds credibility. A good option for replication studies, secondary analyses, and regional cohort studies.

ASN launched Kidney360 as a fully open access journal, and it's become a credible home for nephrology research at various levels. The acceptance rate is more forgiving, and the review process tends to be constructive rather than adversarial. It's particularly welcoming to quality improvement projects, educational innovations, and studies from smaller centers.

CKJ deserves special attention because it offers free open access publishing with no APC. That's rare and valuable. The journal is ERA-linked and indexed in all major databases. Quality is consistent, and the review process is fair. If you need an OA publication without the financial burden, CKJ is a standout choice.

BMC Nephrology is part of the BMC family with a straightforward OA model. It focuses on scientific soundness rather than perceived novelty, which means well-designed studies that confirm or refute existing findings can find a home here. The acceptance rate around 40% reflects this inclusive approach. It's a reasonable option for pilot studies, negative results, and methodological papers.

If your paper is a large multicenter RCT with practice-changing results, send it to JASN or Kidney International first. These are the venues where landmark trials get the attention they deserve.

If your paper is a well-designed observational study with clinical implications, AJKD or CJASN are strong fits. Both value clinical relevance over flashy mechanisms.

If your paper is translational, bridging bench and bedside, Kidney International or JASN will be most receptive. Both journals appreciate work that connects molecular findings to patient outcomes.

If your paper is a single-center cohort study or pilot trial, Kidney International Reports, Kidney360, or American Journal of Nephrology offer realistic targets without sacrificing credibility.

If you're an early-career researcher building your CV, consider Kidney360 or Clinical Kidney Journal. Both provide good visibility and a supportive review process, and CKJ won't cost you anything for OA publication.

If your paper focuses on dialysis or transplant outcomes, NDT should be near the top of your list, especially if your data comes from European populations.